Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Futubull > Quotes > RLYB Rallybio > Company Executives
RLYB Rallybio
NamePositionSalaryService DateEducationAgeGenderUpdated
Dr. Martin W. Mackay, PhDChairman of the Board and Chief Executive Officer838.06K----66male04/25/2022
Dr. Stephen Uden,M.B.President, Chief Operating Officer and Chief Scientific Officer838.06K----64male04/25/2022
Mr. Jeffrey M. Fryer, C.P.A.Principal Accounting Officer, Chief Financial Officer and Treasurer838.06K----52male06/02/2022
Dr. Steven Ryder, M.D.Chief Medical Officer------71male04/25/2022
Dr. Wendy K. Chung, M.D.Director--------male08/02/2022
Mr. Ronald M. HuntIndependent Director------57male04/25/2022
Dr. Robert Hopfner, PhDIndependent Director------49male04/25/2022
Ms. Christine A. NashIndependent Director------49female04/25/2022
Ms. Paula SoteropoulosIndependent Director91.29K----54female04/25/2022
Ms. Helen M. BoudreauIndependent Director98.45K----56female04/25/2022
Dr. Hui Liu, PhDIndependent Director------49male04/25/2022
Dr. Kush M. Parmar, M.D.,PhDIndependent Director------41male04/25/2022
Dr. Lucian Iancovici, M.D.Independent Director------40male04/25/2022
Company Overview More
Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company is also developing RLYB211, a polyclonal anti-HPA-1a antibody that is in a Phase 1/2 clinical trial for the prevention of FNAIT; RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; and RLYB116, a subcutaneously administered inhibitor of C5 for the treatment of patients with paroxysmal nocturnal hemoglobinuria and generalized myasthenia gravis. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.
CEO: MacKay Ph.D., Martin W.
Market: NASDAQ
Futu Hot List
SymbolLatest price%Chg


Back to the Top